Advertisement

ACUR

Acura Pharmaceuticals, Inc.

Healthcare · USD

Set alert

Price alert · ACUR

All alert types
0.00 USD 0.00 0.00%
As of Oct 29, 2026
0.0004 Day range 0.0004
0.0001 52-week range 0.01
YTD
-60.00%
1 year
-60.00%
Open
0.0004
Prev close
0.0002
Mkt cap
13.20K
Vol
400
Avg vol
1.54K
EPS
-0.01
P/E
0.00
Div yield
0.00%
More statistics
Low
0.0004
High
0.0004
Forward P/E
-1.26
Beta
2.06
Short ratio
0.73
Inst. own
19.90%
Dividend
0.00
Ex-div date
Earnings
Jan 2, 2023
50-d avg
0.678571
200-d avg
0.966739
1y target
6.00

2Y chart

Chart tools
Interval
ACUR two-year price chart0.000.190.380.560.75Oct 24Mar 25Aug 25Jan 26Jun 26Oct 26

Key statistics

Market cap
6.89M
Enterprise value
8.78M
Trailing P/E
-0.70
Forward P/E
-1.26
PEG ratio
0.00
Price / sales
2.04
Price / book
0.00
EPS (TTM)
-0.83
Beta
2.06
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-291.24%
Revenue (TTM)
3.38M
Revenue growth
3.80%
Free cash flow
-5.25M
Total cash
4.27M
Total debt
6.19M
Return on equity
-238.90%
Shares outstanding
11.88M
Short % of float
1.20%
50-day average
0.678571
200-day average
0.966739

Analyst view

Consensus: buy

Buy
Price target (mean) 6.00

Next earnings

Jan 2, 2023

Expected Jan 2, 2023. Consensus EPS estimate -0.27.

Earnings history

Financials — quick view

All financials
ACUR Revenue — quarterly 36.00K
2018-Q1 20182018-Q2 20182018-Q3 20182018-Q4 20182019-Q1 20192019-Q2 20192019-Q3 20192019-Q4 20192020-Q1 20202020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 2021
ACUR Net income — quarterly 29.00K
2018-Q1 20182018-Q2 20182018-Q3 20182018-Q4 20182019-Q1 20192019-Q2 20192019-Q3 20192019-Q4 20192020-Q1 20202020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 2021
ACUR EPS — quarterly 0.00
2018-Q1 20182018-Q2 20182018-Q3 20182018-Q4 20182019-Q1 20192019-Q2 20192019-Q3 20192019-Q4 20192020-Q1 20202020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 2021

Earnings

ACUR recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Jan 2, 2023Sep 1, 20220.00———
Nov 15, 2021Sep 1, 20210.000.00——
Aug 16, 2021Jun 1, 20210.00-0.01——

Upgrades / downgrades

ACUR analyst upgrades and downgrades
DateFirmActionFromTo
Feb 26, 2015MLV & CoupHoldBuy
May 27, 2014MLV & CodownBuyHold
Aug 13, 2013MLV & Coinit—Buy

About Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, researches, develops, and commercializes products to address medication abuse and misuse. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; Egalet Ltd.; and Egalet Corporation to manufacture and commercialize Oxaydo products worldwide. The company was founded in 1935 and is based in Palatine, Illinois.

Sector
Healthcare
Industry
Drug Delivery
Country
United States

News

No recent headlines

Headlines appear here as they are published.

Your note

Sign in to keep a note on ACUR — it syncs with the Stock Master app.

Insider holders

ACUR insider holders
InsiderRelationLatest transactionDateShares held
ROSS GEORGE KDirectorOption ExerciseJan 2, 201711,565
SEISER ROBERT AOfficerOption ExerciseFeb 6, 201722,490
SKELLY WILLIAM GDirectorOption ExerciseJan 2, 201728,345
THANGARAJ IMMANUELDirectorOption ExerciseJan 2, 201723,812
WESSON BRUCE FDirectorOption ExerciseJan 2, 201758,670

Institution ownership

ACUR institution ownership
Holder% heldSharesValueReported
Essex Woodlands Health Ventures16.46%1,956,3971.51MDec 30, 2016
Deerfield Management8.63%1,025,641789.74KDec 30, 2016
Vanguard Group, Inc. (The)1.65%195,943150.88KDec 30, 2016
Renaissance Technologies, LLC0.95%113,22087.18KDec 30, 2016
Sabby Management, LLC0.87%103,44479.65KDec 30, 2016
KCG Holdings, Inc.0.38%44,56534.31KDec 30, 2016

Fund ownership

ACUR fund ownership
Holder% heldSharesValueReported
Vanguard Extended Market Index Fund0.75%89,117142.59KSep 29, 2016
Vanguard Total Stock Market Index Fund0.52%61,75998.81KSep 29, 2016
Fidelity Extended Market Index Fund0.16%18,75917.26KNov 29, 2016
iShares Core S&P Total U.S. Stock Market ETF0.08%9,8599.07KNov 29, 2016
Schwab Capital Trust-Total Stock Market Index Fund0.04%4,1808.11KJul 30, 2016
Quantitative Master Series Tr-Extended Market Index Series0.03%3,2045.13KSep 29, 2016
Advertisement